Acurx Pharmaceuticals LLC (ACXP) - Total Assets
Based on the latest financial reports, Acurx Pharmaceuticals LLC (ACXP) holds total assets worth $6.11 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Acurx Pharmaceuticals LLC's book value for net asset value and shareholders' equity analysis.
Acurx Pharmaceuticals LLC - Total Assets Trend (2019–2024)
This chart illustrates how Acurx Pharmaceuticals LLC's total assets have evolved over time, based on quarterly financial data.
Acurx Pharmaceuticals LLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Acurx Pharmaceuticals LLC's total assets of $6.11 Billion consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 96.1% |
| Accounts Receivable | $51.13K | 1.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Acurx Pharmaceuticals LLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ACXP market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Acurx Pharmaceuticals LLC's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 96.1% of total assets in 2024, down from 98.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 1.3% of total assets.
Acurx Pharmaceuticals LLC Competitors by Total Assets
Key competitors of Acurx Pharmaceuticals LLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Acurx Pharmaceuticals LLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.39 | 1.80 | 6.82 |
| Quick Ratio | 2.39 | 1.80 | 6.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.44 Billion | $2.66 Million | $2.75 Million |
Acurx Pharmaceuticals LLC - Advanced Valuation Insights
This section examines the relationship between Acurx Pharmaceuticals LLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.50 |
| Latest Market Cap to Assets Ratio | 1.41 |
| Asset Growth Rate (YoY) | -50.0% |
| Total Assets | $3.86 Million |
| Market Capitalization | $5.45 Million USD |
Valuation Analysis
Above Book Valuation: The market values Acurx Pharmaceuticals LLC's assets above their book value (1.41x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Acurx Pharmaceuticals LLC's assets decreased by 50.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Acurx Pharmaceuticals LLC (2019–2024)
The table below shows the annual total assets of Acurx Pharmaceuticals LLC from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.86 Million | -49.96% |
| 2023-12-31 | $7.71 Million | -17.78% |
| 2022-12-31 | $9.38 Million | -29.25% |
| 2021-12-31 | $13.25 Million | +311.11% |
| 2020-12-31 | $3.22 Million | +27.36% |
| 2019-12-31 | $2.53 Million | -- |
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more